Market Cap
US$320.1m
Last Updated
2021/01/22 23:24 UTC
Data Sources
Company Financials +
Executive Summary
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Mediocre balance sheet with limited growth.
Similar Companies
Share Price & News
How has OncoCyte's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OCX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: OCX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
39.2%
OCX
0.7%
US Biotechs
1.4%
US Market
1 Year Return
70.6%
OCX
40.9%
US Biotechs
22.6%
US Market
Return vs Industry: OCX exceeded the US Biotechs industry which returned 41.5% over the past year.
Return vs Market: OCX exceeded the US Market which returned 22.8% over the past year.
Shareholder returns
| OCX | Industry | Market | |
|---|---|---|---|
| 7 Day | 39.2% | 0.7% | 1.4% |
| 30 Day | 88.1% | 5.2% | 4.9% |
| 90 Day | 186.7% | 23.7% | 14.6% |
| 1 Year | 70.6%70.6% | 43.2%40.9% | 25.4%22.6% |
| 3 Year | 17.5%17.5% | 27.1%20.5% | 46.8%37.0% |
| 5 Year | 14.7%14.7% | 58.4%46.0% | 132.0%106.1% |
Long-Term Price Volatility Vs. Market
How volatile is OncoCyte's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
Read This Before Selling OncoCyte Corporation (NYSEMKT:OCX) Shares2 months ago | Simply Wall St
Industry Analysts Just Made A Meaningful Upgrade To Their OncoCyte Corporation (NYSEMKT:OCX) Revenue Forecasts2 months ago | Simply Wall St
OncoCyte Corporation (NYSEMKT:OCX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their EstimatesValuation
Is OncoCyte undervalued compared to its fair value and its price relative to the market?
9.24x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: OCX ($4.68) is trading above our estimate of fair value ($0.1)
Significantly Below Fair Value: OCX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OCX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: OCX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCX is overvalued based on its PB Ratio (9.1x) compared to the US Biotechs industry average (4.5x).
Next Steps
Future Growth
How is OncoCyte forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
20.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OCX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OCX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OCX's revenue (48.9% per year) is forecast to grow faster than the US market (10.5% per year).
High Growth Revenue: OCX's revenue (48.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has OncoCyte performed over the past 5 years?
-22.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCX is currently unprofitable.
Growing Profit Margin: OCX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OCX is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare OCX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: OCX has a negative Return on Equity (-91.16%), as it is currently unprofitable.
Next Steps
Financial Health
How is OncoCyte's financial position?
Financial Position Analysis
Short Term Liabilities: OCX's short term assets ($12.0M) exceed its short term liabilities ($8.9M).
Long Term Liabilities: OCX's short term assets ($12.0M) do not cover its long term liabilities ($14.2M).
Debt to Equity History and Analysis
Debt Level: OCX's debt to equity ratio (11.9%) is considered satisfactory.
Reducing Debt: OCX's debt to equity ratio has reduced from 36% to 11.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OCX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.5% each year
Next Steps
Dividend
What is OncoCyte current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OCX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OCX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OCX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Ronnie, Ron Andrews (60 yo)
1.5yrs
Tenure
US$2,102,212
Compensation
Mr. Ronald A. Andrews, Jr., also known as Ronnie or Ron, has been Chief Executive Officer and President of OncoCyte Corporation since July 1, 2019 and is its Director since April 2018. Mr. Andrews has been...
CEO Compensation Analysis
Compensation vs Market: Ronnie, Ron's total compensation ($USD2.10M) is about average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Ronnie, Ron's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.5yrs | US$2.10m | 0.15% $ 488.8k | |
| Chief Financial Officer | 3.17yrs | US$1.16m | 0.069% $ 222.3k | |
| no data | US$1.63m | 0.0052% $ 16.6k | ||
| Senior Vice President of Commercial | 1yr | no data | 0.0062% $ 19.9k | |
| Chief Medical Officer | 0.83yr | no data | 0.0079% $ 25.3k | |
| Scientific Advisor | 5.25yrs | US$328.84k | no data | |
| Director of Medical Education | no data | no data | no data |
1.5yrs
Average Tenure
66yo
Average Age
Experienced Management: OCX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.5yrs | US$2.10m | 0.15% $ 488.8k | |
| Independent Director | 5.58yrs | US$130.34k | 0.17% $ 533.3k | |
| Director | 11.33yrs | US$105.34k | 0.56% $ 1.8m | |
| Independent Chairman of the Board | 2.75yrs | US$155.10k | 0.11% $ 337.3k | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Independent Director | 1.5yrs | US$90.34k | no data | |
| Independent Director | 5.08yrs | US$137.84k | 0.034% $ 110.3k | |
| Member of Scientific & Medical Advisory Board | 3.67yrs | no data | no data | |
| Director | 0.42yr | no data | no data | |
| Member of Scientific & Medical Advisory Board | 3.67yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 3.67yrs | no data | no data |
3.7yrs
Average Tenure
60.5yo
Average Age
Experienced Board: OCX's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.1%.
Top Shareholders
Company Information
OncoCyte Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: OncoCyte Corporation
- Ticker: OCX
- Exchange: AMEX
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$320.113m
- Shares outstanding: 67.25m
- Website: https://www.oncocyte.com
Number of Employees
Location
- OncoCyte Corporation
- 15 Cushing
- Irvine
- California
- 92618
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OCX | AMEX (NYSE MKT LLC) | Yes | Common Shares | US | USD | Dec 2015 |
| 7OC | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Dec 2015 |
| 0KCC | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Dec 2015 |
Biography
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 23:24 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.